NASDAQ:NTLA - Intellia Therapeutics Stock Price, Price Target & More

$21.94 -0.79 (-3.48 %)
(As of 04/20/2018 02:53 AM ET)
Previous Close$21.94
Today's Range$21.75 - $23.0788
52-Week Range$11.15 - $35.99
Volume703,294 shs
Average Volume1.12 million shs
Market Capitalization$973.22 million
P/E Ratio-11.67
Dividend YieldN/A
Beta2.83

About Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics logoIntellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTLA
CUSIPN/A
Phone857-285-6200

Debt

Debt-to-Equity RatioN/A
Current Ratio11.32%
Quick Ratio11.32%

Price-To-Earnings

Trailing P/E Ratio-11.67
Forward P/E Ratio-9.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.12 million
Price / Sales35.61
Cash FlowN/A
Price / CashN/A
Book Value$8.33 per share
Price / Book2.63

Profitability

EPS (Most Recent Fiscal Year)($1.88)
Net Income$-67,540,000.00
Net Margins-258.62%
Return on Equity-31.27%
Return on Assets-23.10%

Miscellaneous

Employees195
Outstanding Shares42,390,000

How to Become a New Pot Stock Millionaire

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics (NASDAQ:NTLA) issued its quarterly earnings results on Wednesday, March, 14th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.16. The business had revenue of $6.70 million for the quarter, compared to analysts' expectations of $8.84 million. Intellia Therapeutics had a negative return on equity of 31.27% and a negative net margin of 258.62%. The firm's revenue for the quarter was up 19.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.31) earnings per share. View Intellia Therapeutics' Earnings History.

What price target have analysts set for NTLA?

9 brokerages have issued 1 year price targets for Intellia Therapeutics' shares. Their forecasts range from $20.00 to $46.00. On average, they expect Intellia Therapeutics' stock price to reach $34.8333 in the next year. View Analyst Ratings for Intellia Therapeutics.

What are Wall Street analysts saying about Intellia Therapeutics stock?

Here are some recent quotes from research analysts about Intellia Therapeutics stock:
  • 1. According to Zacks Investment Research, "Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. " (10/4/2017)
  • 2. Cann analysts commented, "Loss per share was $0.45 compared to our estimated loss of $0.39. This was the result of lower than expected Collaborative revenue of $5.9 million compared to our estimate of $6.5 million and higher than estimated R&D expenses of $15.6 million compared to our estimated $14.1 million. Lower revenue and higher expenses were partially offset by a higher than estimated shares outstanding. There were no other meaningful variances in the quarter. Our outlook remains basically unchanged. We have made modest adjustments to our estimated shares outstanding and R&D expense." (8/1/2017)

Who are some of Intellia Therapeutics' key competitors?

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the folowing people:
  • Dr. John M. Leonard, Pres & CEO (Age 61)
  • Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 32)
  • Mr. José E. Rivera J.D., Esq., Exec. VP of Operations and Gen. Counsel (Age 52)
  • Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board
  • Dr. Jennifer A. Doudna, Founder & Member of Scientific Advisor Board (Age 54)

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Has Intellia Therapeutics been receiving favorable news coverage?

News articles about NTLA stock have been trending positive recently, Accern reports. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intellia Therapeutics earned a daily sentiment score of 0.36 on Accern's scale. They also gave media stories about the company an impact score of 48.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include ORBIMED ADVISORS LLC (5.99%) and ORBIMED ADVISORS LLC (4.99%). Company insiders that own Intellia Therapeutics stock include Bros Advisors Lp Baker, Caribou Biosciences, Inc, Carl L Gordon, Institutes For Biomed Novartis, Jean Francois Formela, Nessan Bermingham and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Intellia Therapeutics.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $21.94.

How big of a company is Intellia Therapeutics?

Intellia Therapeutics has a market capitalization of $973.22 million and generates $26.12 million in revenue each year. The company earns $-67,540,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Intellia Therapeutics employs 195 workers across the globe.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]


MarketBeat Community Rating for Intellia Therapeutics (NTLA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe NTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intellia Therapeutics (NASDAQ:NTLA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Intellia Therapeutics in the last 12 months. Their average twelve-month price target is $34.8333, suggesting that the stock has a possible upside of 58.77%. The high price target for NTLA is $46.00 and the low price target for NTLA is $20.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.632.63
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $34.8333$34.8333$30.1667$26.80
Price Target Upside: 58.77% upside32.70% upside64.22% upside12.19% downside

Intellia Therapeutics (NASDAQ:NTLA) Consensus Price Target History

Price Target History for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ:NTLA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2018WedbushReiterated RatingOutperform$36.00HighView Rating Details
3/14/2018Leerink SwannReiterated RatingOutperformHighView Rating Details
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform -> OutperformHighView Rating Details
3/7/2018BarclaysBoost Price TargetOverweight -> Overweight$33.00 -> $46.00MediumView Rating Details
12/18/2017OppenheimerReiterated RatingHoldLowView Rating Details
11/3/2017Credit Suisse GroupBoost Price TargetOutperform$24.00 -> $28.00N/AView Rating Details
10/31/2017Jefferies GroupSet Price TargetBuy -> Buy$36.00 -> $42.00N/AView Rating Details
8/29/2017Chardan CapitalDowngradeBuy -> Neutral$20.00HighView Rating Details
8/1/2017CannReiterated RatingHoldMediumView Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Intellia Therapeutics (NASDAQ:NTLA) Earnings History and Estimates Chart

Earnings by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ:NTLA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.55)($0.52)($0.54)
Q2 20182($0.58)($0.57)($0.58)
Q3 20182($0.51)($0.30)($0.41)
Q4 20183($0.55)($0.33)($0.45)

Intellia Therapeutics (NASDAQ NTLA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018Q4 2017($0.45)($0.61)$8.84 million$6.70 millionViewN/AView Earnings Details
10/31/2017Q3 2017($0.4960)($0.44)$5.83 million$7.30 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.4150)($0.45)$5.83 million$5.90 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.34)($0.3640)$5.30 million$6.22 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.21)($0.3060)$5.63 million$5.63 millionViewN/AView Earnings Details
11/1/2016Q3 2016($0.22)($0.22)$4.55 million$4.90 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.10)($0.36)$6.34 million$4.21 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Intellia Therapeutics (NASDAQ:NTLA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Intellia Therapeutics (NASDAQ NTLA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.80%
Institutional Ownership Percentage: 58.48%
Insider Trading History for Intellia Therapeutics (NASDAQ:NTLA)
Insider Trading History for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ NTLA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/20/2018Jean Francois FormelaDirectorSell39,245$23.87$936,778.15View SEC Filing  
1/29/2018Caribou Biosciences, Inc.Major ShareholderSell550,645$26.78$14,746,273.10View SEC Filing  
12/12/2017Institutes For Biomed NovartisMajor ShareholderSell1,523,000$18.30$27,870,900.00View SEC Filing  
12/8/2017Nessan BerminghamCEOSell336,783$20.78$6,998,350.74696,000View SEC Filing  
12/6/2017Nessan BerminghamCEOSell111,500$20.34$2,267,910.00696,000View SEC Filing  
7/11/2017Venture Fund Ix L.P. AtlasMajor ShareholderSell150,000$16.24$2,436,000.00View SEC Filing  
3/10/2017Jean Francois FormelaDirectorSell21,132$13.91$293,946.12View SEC Filing  
5/11/2016Bros. Advisors Lp BakerInsiderBuy200,000$18.00$3,600,000.00View SEC Filing  
5/11/2016Carl L GordonDirectorBuy250,000$18.00$4,500,000.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intellia Therapeutics (NASDAQ NTLA) News Headlines

Source:
DateHeadline
Why Intellia Therapeutics, Inc. Stock Lost 19.2% in MarchWhy Intellia Therapeutics, Inc. Stock Lost 19.2% in March
finance.yahoo.com - April 13 at 9:41 AM
Intellia Therapeutics (NTLA) Upgraded at ValuEngineIntellia Therapeutics (NTLA) Upgraded at ValuEngine
www.americanbankingnews.com - April 12 at 10:18 PM
Intellia Therapeutics (NTLA) Cut to "Neutral" at Chardan CapitalIntellia Therapeutics (NTLA) Cut to "Neutral" at Chardan Capital
www.americanbankingnews.com - April 9 at 8:06 PM
Intellia Therapeutics Inc (NTLA) Expected to Post Quarterly Sales of $6.14 MillionIntellia Therapeutics Inc (NTLA) Expected to Post Quarterly Sales of $6.14 Million
www.americanbankingnews.com - April 8 at 5:19 AM
Intellia Therapeutics Inc (NTLA) Expected to Post Earnings of -$0.56 Per ShareIntellia Therapeutics Inc (NTLA) Expected to Post Earnings of -$0.56 Per Share
www.americanbankingnews.com - April 6 at 1:20 AM
Time Out: Talking Strategy For CRISPRs Big 3Time Out: Talking Strategy For CRISPR's Big 3
seekingalpha.com - April 4 at 4:54 PM
Oops! CRISPR Concerns Turn Out to be a Big NothingburgerOops! CRISPR Concerns Turn Out to be a Big Nothingburger
finance.yahoo.com - April 3 at 9:36 AM
Intellia Therapeutics Inc (NTLA) Given Average Recommendation of "Buy" by BrokeragesIntellia Therapeutics Inc (NTLA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 28 at 10:16 AM
Intellia Therapeutics Inc (NTLA) Director Jean Francois Formela Sells 39,245 SharesIntellia Therapeutics Inc (NTLA) Director Jean Francois Formela Sells 39,245 Shares
www.americanbankingnews.com - March 22 at 4:17 PM
Intellia Therapeutics Inc (NTLA) Expected to Announce Quarterly Sales of $6.14 MillionIntellia Therapeutics Inc (NTLA) Expected to Announce Quarterly Sales of $6.14 Million
www.americanbankingnews.com - March 22 at 9:00 AM
Intellia Therapeutics (NTLA) Downgraded by BidaskClub to BuyIntellia Therapeutics (NTLA) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - March 21 at 11:48 PM
Intellia Therapeutics (NTLA) Raised to "C-" at TheStreetIntellia Therapeutics (NTLA) Raised to "C-" at TheStreet
www.americanbankingnews.com - March 21 at 1:10 PM
Intellia Therapeutics (NTLA) Upgraded at BidaskClubIntellia Therapeutics (NTLA) Upgraded at BidaskClub
www.americanbankingnews.com - March 18 at 5:38 PM
Intellia Therapeutics (NTLA) Rating Reiterated by Leerink SwannIntellia Therapeutics (NTLA) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - March 16 at 9:54 PM
3 Reasons CRISPR Stocks Could Keep Soaring - Motley Fool3 Reasons CRISPR Stocks Could Keep Soaring - Motley Fool
www.fool.com - March 16 at 5:33 PM
Intellia Therapeutics Inc (NTLA) Expected to Earn Q4 2018 Earnings of ($0.46) Per ShareIntellia Therapeutics Inc (NTLA) Expected to Earn Q4 2018 Earnings of ($0.46) Per Share
www.americanbankingnews.com - March 16 at 12:36 PM
Wedbush Reaffirms Outperform Rating for Intellia Therapeutics (NTLA)Wedbush Reaffirms Outperform Rating for Intellia Therapeutics (NTLA)
www.americanbankingnews.com - March 15 at 2:05 PM
Mid-Afternoon Market Update: Intellia Therapeutics Slides Following Q4 Results; Arcadia Biosciences Shares Surge - NasdaqMid-Afternoon Market Update: Intellia Therapeutics Slides Following Q4 Results; Arcadia Biosciences Shares Surge - Nasdaq
www.nasdaq.com - March 14 at 5:52 PM
Headcount soars at Cambridge gene editing biotechs Editas, Intellia ... - Boston Business JournalHeadcount soars at Cambridge gene editing biotechs Editas, Intellia ... - Boston Business Journal
www.bizjournals.com - March 14 at 5:52 PM
Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 14 at 5:52 PM
Intellia Therapeutics Inc’s (NASDAQ:NTLA) Earnings Dropped -105.74%, How Did It Fare Against The Industry?Intellia Therapeutics Inc’s (NASDAQ:NTLA) Earnings Dropped -105.74%, How Did It Fare Against The Industry?
finance.yahoo.com - March 14 at 5:52 PM
Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial ResultsIntellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 14 at 10:17 AM
Intellia Therapeutics (NTLA) Releases Quarterly  Earnings ResultsIntellia Therapeutics (NTLA) Releases Quarterly Earnings Results
www.americanbankingnews.com - March 14 at 9:48 AM
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia TherapeuticsZacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
finance.yahoo.com - March 13 at 9:36 AM
Is a Surprise Coming for Intellia Therapeutics (NTLA)This Earnings Season?Is a Surprise Coming for Intellia Therapeutics (NTLA)This Earnings Season?
finance.yahoo.com - March 9 at 9:49 AM
Intellia Therapeutics (NTLA) Earns Outperform Rating from Analysts at JMP SecuritiesIntellia Therapeutics (NTLA) Earns Outperform Rating from Analysts at JMP Securities
www.americanbankingnews.com - March 8 at 11:40 PM
Intellia Therapeutics (NTLA) Price Target Raised to $46.00Intellia Therapeutics (NTLA) Price Target Raised to $46.00
www.americanbankingnews.com - March 7 at 2:49 PM
Intellia Therapeutics Inc (NTLA) Expected to Post Quarterly Sales of $9.17 MillionIntellia Therapeutics Inc (NTLA) Expected to Post Quarterly Sales of $9.17 Million
www.americanbankingnews.com - March 4 at 2:02 AM
Intellia Therapeutics Inc (NTLA) Given Average Rating of "Hold" by AnalystsIntellia Therapeutics Inc (NTLA) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 3 at 12:26 PM
-$0.48 EPS Expected for Intellia Therapeutics Inc (NTLA) This Quarter-$0.48 EPS Expected for Intellia Therapeutics Inc (NTLA) This Quarter
www.americanbankingnews.com - March 2 at 9:24 PM
VBs Holdings Could Mean 11% Gain Potential - NasdaqVB's Holdings Could Mean 11% Gain Potential - Nasdaq
www.nasdaq.com - March 2 at 5:13 PM
Intellia Therapeutics to Present at March Healthcare Investor Conferences - GlobeNewswire (press release)Intellia Therapeutics to Present at March Healthcare Investor Conferences - GlobeNewswire (press release)
globenewswire.com - March 2 at 5:13 PM
FY2022 Earnings Forecast for Intellia Therapeutics Inc Issued By Oppenheimer (NTLA)FY2022 Earnings Forecast for Intellia Therapeutics Inc Issued By Oppenheimer (NTLA)
www.americanbankingnews.com - March 1 at 4:08 PM
Intellia Therapeutics to Present at March Healthcare Investor ConferencesIntellia Therapeutics to Present at March Healthcare Investor Conferences
finance.yahoo.com - February 28 at 5:07 PM
Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery TechnologyIntellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology
finance.yahoo.com - February 27 at 5:09 PM
ARK Investment Management LLC Has $26.43 Million Stake in Intellia Therapeutics Inc (NTLA)ARK Investment Management LLC Has $26.43 Million Stake in Intellia Therapeutics Inc (NTLA)
www.americanbankingnews.com - February 26 at 5:12 AM
Analyzing Alkermes (ALKS) & Intellia Therapeutics (NTLA)Analyzing Alkermes (ALKS) & Intellia Therapeutics (NTLA)
www.americanbankingnews.com - February 17 at 5:12 AM
Intellia Therapeutics (NTLA) Stock Rating Upgraded by BidaskClubIntellia Therapeutics (NTLA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 11 at 8:10 AM
Here's What Pushed Intellia Therapeutics Inc. Up 33.7% in JanuaryHere's What Pushed Intellia Therapeutics Inc. Up 33.7% in January
finance.yahoo.com - February 8 at 4:18 PM
Heres What Pushed Intellia Therapeutics Inc. Up 33.7% in JanuaryHere's What Pushed Intellia Therapeutics Inc. Up 33.7% in January
www.fool.com - February 8 at 1:42 PM
Intellia Therapeutics Inc (NTLA) Given Average Rating of "Hold" by BrokeragesIntellia Therapeutics Inc (NTLA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 6 at 9:14 AM
Intellia Therapeutics to Present at February Healthcare Investor ConferencesIntellia Therapeutics to Present at February Healthcare Investor Conferences
finance.yahoo.com - February 1 at 9:20 AM
Insider Selling: Intellia Therapeutics Inc (NTLA) Major Shareholder Sells 550,645 Shares of StockInsider Selling: Intellia Therapeutics Inc (NTLA) Major Shareholder Sells 550,645 Shares of Stock
www.americanbankingnews.com - January 30 at 6:14 PM
$9.17 Million in Sales Expected for Intellia Therapeutics Inc (NTLA) This Quarter$9.17 Million in Sales Expected for Intellia Therapeutics Inc (NTLA) This Quarter
www.americanbankingnews.com - January 30 at 6:52 AM
 Brokerages Expect Intellia Therapeutics Inc (NTLA) to Announce -$0.43 EPS Brokerages Expect Intellia Therapeutics Inc (NTLA) to Announce -$0.43 EPS
www.americanbankingnews.com - January 28 at 7:18 AM
Intellia Therapeutics Inc (NTLA) Receives Average Recommendation of "Hold" from AnalystsIntellia Therapeutics Inc (NTLA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 12 at 8:02 AM
-$0.43 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter-$0.43 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter
www.americanbankingnews.com - January 11 at 8:18 AM
Heres Why Intellia Therapeutics Inc. Fell 14.7% in DecemberHere's Why Intellia Therapeutics Inc. Fell 14.7% in December
www.fool.com - January 4 at 5:15 PM
Here's Why Intellia Therapeutics Inc. Fell 14.7% in DecemberHere's Why Intellia Therapeutics Inc. Fell 14.7% in December
finance.yahoo.com - January 4 at 5:15 PM
Intellia Therapeutics (NTLA) Upgraded to Hold at BidaskClubIntellia Therapeutics (NTLA) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - December 29 at 9:30 AM

SEC Filings

Intellia Therapeutics (NASDAQ:NTLA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intellia Therapeutics (NASDAQ:NTLA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intellia Therapeutics (NASDAQ NTLA) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.